欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (7): 781-784.

• 研究原著 • 上一篇    下一篇

一氧化氮藕联的塞曲司特衍生物抗哮喘活性的研究

邱苏赣, 季晖, 张奕华1, 张志国1   

  1. 中国药科大学药理学教研室, 1新药研究中心, 南京210009, 江苏
  • 收稿日期:2003-11-17 修回日期:2004-03-26 出版日期:2004-07-26 发布日期:2020-11-20
  • 通讯作者: 季晖,女,教授,博士生导师,研究方向:抗衰老药理和重大疾病NO调控剂的研究。Tel:025-83271250 E-mail:huijicpu@163.com

Study on antiasthmatic activity of seratrodast derivative connected with NO donors

QIU Su-Gan, JI Hui, ZHANG Yi-Hua1, ZHANG Zhi-Guo1   

  1. Department of Pharmacology ,1Centre of Drug Discovery, China Pharmaceutical University, Nanjing 210009, Jiangsu,China
  • Received:2003-11-17 Revised:2004-03-26 Online:2004-07-26 Published:2020-11-20

摘要: 目的: 研究与一氧化氮供体(NO)藕联的塞曲司特衍生物(SDF-1、SDG-1、SDG-3)的抗哮喘活性。其中F-1 为呋咱氧氮类化合物,G-1、G-3 为羟基胍类化合物,SDF-1 为F-1 和塞曲司特连接而成的藕联化合物,SDG-1 为G-1 和塞曲司特的藕联化合物,SDG-3 为G-3 和塞曲司特的藕联化合物。方法: 以豚鼠乙酰胆碱-组胺引喘法观察其整体抗哮喘作用;以Griess 法测定其体外NO 释放量;以离体豚鼠气管条法测定其舒张气管作用。结果: 在1.25mg·kg-1的剂量下,SDF-1 的引喘潜伏期与塞曲司特有极显著差异(P<0.01),SDG-1 和SDG-3 与塞曲司特有显著差异(P<0.05)。SDF-1、SDG-1 体外NO 释放量高于其前体药物F-1、G-1,SDG-3 则低于其前体G-3 。在卡巴胆碱作为收缩剂时,SDF-1 和SDG-1 舒张离体豚鼠气管平滑肌的半数有效浓度和最大舒张率均与塞曲司特及相应前体有极显著差异(P<0.01),SDG-3 的半数有效浓度和最大舒张率与塞曲司特有极显著差异(P<0.01)。在磷酸组胺作为收缩剂时SDF-1、SDG-1 和SDG-3 舒张豚鼠离体气管平滑肌的半数有效浓度和最大舒张率均与塞曲司特及相应前体有极显著差异(P<0.01)。结论: 新化合物较两种前体—塞曲司特及单一的NO 供体具有更强的抗哮喘活性。

关键词: 塞曲司特, 呋咱氮氧类化合物, 羟基胍类化合物, 抗哮喘, 一氧化氮

Abstract: AIM: To estimate the antiasthmatic activity of new compounds :SDF-1, SDG-1 and SDG-3.F-1 is a furoxan derivative, G-1 and G-3 are hydroxylguanidine derivatives, SDF-1 is a novel seratrodast derivative connected with F-1, SDG-1 a seratrodast derivative connected with G-1, and SDG-3 a novel seratrodast derivative connected with G-3.METHODS: Firstly, the in vivo antiasthmatic activity was estimated in asthmatic guinea pigs induced by acetylcholine and histamine.Secondly, the in vitro NO releasement of these compounds was determined following the procedures of Griess.Finally, tracheal smooth muscle relexant potency of these compounds was evaluated on trachea of guinea pigs.RESULTS: The in vivo antiasthmatic activity of SDF-1 was more potent than seratrodast (P<0.01), and SDG-1 and SDG-3 were slightly more potent than seratrodast (P<0.05).The in vitro NO releasement of SDF-1 and SDG-1 was higher than F-1 and G-1, the original compounds of SDF-1 and SDG-1, while SDG-3 was lower than its original compounds G-3.In the evaluation on trachea contracted by carbcholine, SDF-1 and SDG-1 were more potent than seratrodast, F-1 and G-1 (P<0.01), but SDG-3 only slightly more potent than seratrodast (P<0.01).In the evaluation on trachea contracted by histamine, SDF-1, SDG-1 and SDG-3 were slightly more potent than seratrodast and their original compounds (P<0.01).CONCLUSION: The antiasthmatic activity of new compounds are more potent than seratrodast and their original NO donors.

Key words: seratrodast, furoxan derivatives, NHydroxyguanidine, antiasthma, NO in vitro releasement

中图分类号: